iThera Medical, a Munich Germany-based company that develops and markets a novel in-vivo biomedical imaging technology, recently closed a Series A funding round of undisclosed amount.
Backers include BayBG Bayerische Beteiligungsgesellschaft mbH, and Mey Capital Matrix GmbH.
Earlier this year, the company also secured a Phase II grant from the GO-Bio programme, which is funded by the German Ministry of Education and Research (BMBF) and managed by Projektträger Jülich.
iThera, a spin-off from the Helmholtz Zentrum München, plans to use the funds to further develop and commercialize its technology for preclinical and clinical applications. Ascenion, the Helmholtz Zentrum’s technology transfer partner, has actively supported the company’s foundation and funding and holds equity in the company.
iThera’s multispectral optoacoustic tomography (MSOT) was invented by Prof. Dr Vasilis Ntziachristos and Dr Daniel Razansky at the Helmholtz Zentrum München, and enables the non-invasive, real-time visualization of anatomical, functional and molecular information in living tissue, at depths and at a resolution not achievable by optical imaging methods, according to the company. MSOT currently allows the early and reliable validation of new substance efficacy in drug discovery (e.g., for oncology, neurology and cardio-vascular problems). In the future, it also promises to become a valuable tool in clinical diagnostics.
The company is led by Christian Wiest, co-founder and CEO.
FinSMEs
23/11/2011